Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Cash from Financing Activities (2016 - 2025)

Orthofix Medical's Cash from Financing Activities history spans 16 years, with the latest figure at $2.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 92.45% year-over-year to $2.4 million, compared with a TTM value of -$786000.0 through Dec 2025, down 101.55%, and an annual FY2025 reading of -$786000.0, down 101.55% over the prior year.
  • Cash from Financing Activities for Q4 2025 was $2.4 million at Orthofix Medical, up from -$5.2 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $31.5 million in Q4 2024, with the low at -$7.6 million in Q2 2021.
  • Average Cash from Financing Activities over 5 years is $5.6 million, with a median of $1.3 million recorded in 2021.
  • Year-over-year, Cash from Financing Activities tumbled 301.17% in 2022 and then skyrocketed 7342.46% in 2023.
  • Tracing OFIX's Cash from Financing Activities over 5 years: stood at $2.1 million in 2021, then dropped by 27.0% to $1.5 million in 2022, then soared by 1587.58% to $25.3 million in 2023, then increased by 24.55% to $31.5 million in 2024, then plummeted by 92.45% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for OFIX's Cash from Financing Activities are $2.4 million (Q4 2025), -$5.2 million (Q3 2025), and $2.6 million (Q2 2025).